DNTH - NASDAQ
Dianthus Therapeutics, Inc.
$84.97
-1.5%Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
At a Glance
Live SnapshotDianthus Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Dianthus Therapeutics, Inc. Income Statement
DNTH • NASDAQ
| Dianthus Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||
2M | 6.2M | 2.8M | 6.4M | 1.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (2M) | (1.8M) | (875K) | (376K) | (6K) | |
2M | 6.2M | 2.8M | 6.4M | 1.5M | -2M | -1.8M | -875K | -376K | -6K | |
OPERATING INCOME | ||||||||||
(180M) | (108.1M) | (51M) | (36.1M) | (14.6M) | (76.7M) | (81.1M) | (59.1M) | (35.4M) | (9.3M) | |
(34.3M) | (25M) | (18.2M) | (6.7M) | (2M) | (28.1M) | (23.8M) | (17.7M) | (7.5M) | (3.5M) | |
(145.6M) | (83.1M) | (32.8M) | (29.4M) | (12.6M) | (48.6M) | (57.4M) | (41.3M) | (27.9M) | (5.8M) | |
-177.9M | -101.9M | -48.2M | -29.7M | -13.1M | -78.7M | -83M | -60M | -35.7M | -9.3M | |
PRE-TAX INCOME | ||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (3.8M) | (0.0) | (0.0) | (0.0) | (163K) | |
16.1M | 17.4M | 4.8M | 1.1M | 100K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
15.6M | 16.9M | 4.6M | 1.2M | -23K | 3.8M | 6.2M | 2.4M | 236K | -163K | |
-162.3M | -85M | -43.6M | -28.5M | -13.1M | -74.9M | -76.8M | -57.5M | -35.5M | -9.4M | |
NET INCOME | ||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (236K) | (0.0) | |
-162.3M | -85M | -43.6M | -28.5M | -13.1M | -74.9M | -76.8M | -57.5M | -35.5M | -9.4M |
SEC Filings
DNTH - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 09, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 10, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 09, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
S-3 S-3 N/A | January 28, 2026 | January 28, 2026 | ||
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 |
Related Guides
Continue your DNTH research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.